Tissue Microarray Market Report 2026

Tissue Microarray Market Overview

• Tissue Microarray market size has reached to $13.11 billion in 2025 • Expected to grow to $23.61 billion in 2030 at a compound annual growth rate (CAGR) of 12.6% • Growth Driver: Surge In Personalized Medicine Demand Propelling Tissue Microarray Growth • Market Trend: Innovations In Tissue Microarray Technology • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tissue Microarray Market?

Tissue microarray refers to high-throughput technology that enables thorough analysis of an antigen's expression across numerous tissues and cells in a single experiment using paraffin blocks or formalin. Tissue microarrays are used to simultaneously assess the protein expression of multiple tissue samples. The main types of tissue microarrays are immunohistochemistry, fluorescent in situ hybridization, frozen tissue array, and others. Immunohistochemistry (IHC) refers to a technique used to diagnose certain types of cancer, including mesothelioma by using a visual marker to locate antigens in biopsy tissue. Deoxyribonucleic acid (DNA) microarray, polymerase chain reaction (PCR), next-generation sequencing, northern blotting, and western blotting technologies are used for oncology, gene expression profiling, single nucleotide polymorphism (SNP) detection, double-stranded B-DNA microarrays, comparative genomic hybridization, and sequencing bioinformatics applications by various end-users including pharmaceutical and biotechnological companies, research organization, and hospitals.

What Is The Tissue Microarray Market Growth Forecast?

The tissue microarray market size is expected to see rapid growth in the next few years. It will grow to $23.61 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to increasing investments in precision oncology research, rising adoption of digital pathology solutions, expansion of translational research initiatives, growing demand for multi-omics analysis, increasing use of tissue microarrays in drug discovery. Major trends in the forecast period include increasing use of high-throughput tissue analysis platforms, rising adoption of multiplex immunohistochemistry, growing demand for standardized tissue arrays, expansion of automated tissue microarray construction, enhanced integration with molecular diagnostics.

Global Tissue Microarray Market Segmentation

1) By Type: Immunohistochemistry, Fluorescent In Situ Hybridization, Frozen Tissue Array, Other Types 2) By Technology: Immunohistochemistry (IHC)–Based Detection, In Situ Hybridization (ISH) Technologies, Digital Pathology and Image Analysis, Tissue Microarray Construction Technologies, Signal Detection and Visualization Technologies 3) By Application: Oncology Research and Biomarker Validation, Drug Discovery and Development, Translational and Clinical Research, Protein Expression and Localization Analysis, Gene and RNA Expression Analysis (Tissue-Based), Comparative Pathology and Toxicology Studies 4) By End-User: Pharmaceutical And Biotechnological Companies, Research Organizations, Hospitals Subsegments: 1) By Immunohistochemistry: Automated Immunohistochemistry, Manual Immunohistochemistry, Multiplex Immunohistochemistry 2) By Fluorescent In Situ Hybridization (FISH): Single-Color FISH, Multi-Color FISH, DNA FISH 3) By Frozen Tissue Array: Tissue Microarray from Frozen Samples, Snap-Frozen Tissue Array 4) By Other Types: RNA In Situ Hybridization, Paraffin-Embedded Tissue Array

What Is The Driver Of The Tissue Microarray Market?

Rising demand for personalized medicine is expected to propel the growth of the tissue microarray market going forward. Personalized medicine tailors medical treatment to individual characteristics for more effective and precise healthcare. Personalized medicine utilizes tissue microarrays to analyze multiple tissue samples concurrently, facilitating rapid and efficient assessment of biomarkers for tailored patient treatments. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, the USFDA approved 16 new personalized treatments for rare disease patients in 2023, a significant increase from 6 personalized treatments in 2022. Therefore, the rising demand for personalized medicine is driving the growth of the tissue microarray industry.

Key Players In The Global Tissue Microarray Market

Major companies operating in the tissue microarray market are BioIVT LLC, BioChain Institute Inc., Creative Bioarray Co., 3DHISTECH Ltd., OriGene Technologies Inc., Bio SB Inc., ProteoGenex Inc., US Biomax Inc., AMS Biotechnology Ltd., TissueArray.Com LLC, Pantomics Inc., Zyagen Inc., Asterand Bioscience, Indivumed GmbH, PrecisionMed Inc., Conversant Bio AB, RayBiotech Life Inc., Novus Biologicals LLC, Tristar Group, iSpecimen Inc.

Global Tissue Microarray Market Trends and Insights

Major companies operating in the tissue microarray market are focusing on advanced solutions, such as microarray platforms to enhance precision and efficiency in high-throughput tissue analysis. A microarray platform is a technology that allows for simultaneous analysis of multiple genes or other biomolecules on a small surface, facilitating genetic and expression studies. For instance, in June 2023, MARGenomics, a Spain-based hospital del Mar medical research institute, launched the Applied Biosystems GeneChip 3000 Dx v2, an advanced microarray platform funded by the Carlos III Health Institute (ISCIII) and the European Union's NextGenerationEU initiative. It is the inaugural microarray platform in both Europe and the United States to receive regulatory approval for diagnostic purposes, attaining IVD-R (In Vitro Diagnosis Regulation) certification. The system boasts diverse functionalities, encompassing genomic and expression microarrays.

What Are Latest Mergers And Acquisitions In The Tissue Microarray Market?

In May 2024, Bruker Corporation, a US-based provider of high-performance scientific instruments and analytical solutions, acquired NanoString Technologies for approximately $392.6 million. With this acquisition, Bruker aims to expand its spatial biology and transcriptomics capabilities, strengthen its position in high-plex tissue analysis, and enhance its technology portfolio used in advanced tissue-based and translational research workflows. NanoString Technologies is a US-based provider of spatial transcriptomics, single-cell imaging, and gene-expression analysis platforms widely used for whole-tissue and tissue-microarray-based research applications.

Regional Outlook

North America was the largest region in the tissue microarray market in 2025. Asia-Pacific is expected to be the fastest-growing region in the tissue microarray market report during the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Tissue Microarray Market?

The tissue microarray market consists of sales of molds, needles, and tissue punches. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.